# Zoetis Inc. – Consensus ‘buy’ rating and 19.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/zoetis-inc.consensus-buy-rating-and-19.5-upside-potential/4121166230
- Published: 2024-07-26T13:05:20+01:00
- Author: Charlotte Edwards

**Zoetis Inc.** which can be found using ticker (ZTS) now have 15 analysts in total
covering the stock. The consensus rating is pointing to ‘buy’. The range between
the high target price and low target price is between $248.00 and $180.00 calculating
the average target price we see $214.74. Given that the stocks previous close was
at $179.66 this would imply there is now a potential upside of 19.5%. The 50 day
MA is $174.39 and the 200 day moving average is $177.00. The total market capitalization
for the company now stands at 82.48B. The stock price for the company is currently
$180.76 USD

 The potential market cap would be $98,584,715,085 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 34.83, revenue per share of $19.00
and a 13.99% return on assets.

Zoetis Inc. is an animal health company. The Company is focused on the discovery,
development, manufacture and commercialization of medicines, vaccines, diagnostic
products and services, biodevices, genetic tests and precision animal health technology.
It commercializes products across eight core species: dogs, cats and horses and 
cattle, swine, poultry, fish and sheep and within product categories, such as vaccines,
anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated
feed additives and animal health diagnostics. The Company operates through two segments:
the United States and International. Within each of these operating segments, it
offers a product portfolio for both companion animal and livestock customers. The
Company market its products in approximately 45 countries across North America, 
Europe, Africa, Asia, Australia and South America. The Company’s products are sold
in more than 100 countries.

Share on: